Malta - engelsk - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - zonisamide - hard capsule - zonisamide 25 mg - antiepileptics

Malta - engelsk - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - zonisamide - hard capsule - zonisamide 50 mg - antiepileptics

Malta - engelsk - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - zonisamide - hard capsule - zonisamide 100 mg - antiepileptics

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lorazepam 0.5mg (3% overage added) - tablet - 0.5 mg - active: lorazepam 0.5mg (3% overage added) excipient: indigo carmine lactose monohydrate magnesium stearate microcrystalline cellulose polacrilin potassium - ativan (lorazepam) is useful in the therapy of most disorders in which anxiety is a major component. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. treatment of moderate to severe anxiety.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lorazepam 1mg;   - tablet - 1 mg - active: lorazepam 1mg   excipient: lactose monohydrate magnesium stearate microcrystalline cellulose polacrilin potassium - ativan (lorazepam) is useful in the therapy of most disorders in which anxiety is a major component. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. treatment of moderate to severe anxiety.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lorazepam 2.5mg;   - tablet - 2.5 mg - active: lorazepam 2.5mg   excipient: lactose monohydrate magnesium stearate microcrystalline cellulose polacrilin potassium - ativan (lorazepam) is useful in the therapy of most disorders in which anxiety is a major component. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. treatment of moderate to severe anxiety.

Den europeiske union - engelsk - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

Den europeiske union - engelsk - EMA (European Medicines Agency)

takeda pharma a/s - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.after initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Den europeiske union - engelsk - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin, pioglitazone - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus: , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone. , in addition, incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination. after initiation of therapy with incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, incresync should be discontinued. in light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of incresync is maintained (see section 4.4).,

Den europeiske union - engelsk - EMA (European Medicines Agency)

1 a pharma gmbh - rivastigmine - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.